RALEIGH, N.C., June 17 /PRNewswire/ -- Pharmaceutical Institute (PI), a leading provider of specialized training solutions for the pharmaceutical and biotech industry, today announced the release of a new e-course titled, Introduction to Health Policy. The course is the newest addition to the company's Managed Markets Excellence(TM) series. The new Introduction to Health Policy e-course provides a comprehensive overview of the challenges confronting the US healthcare system.
"As politicians and policy makers continue to debate options to reform our healthcare system, pharmaceutical and biotech companies are working to understand the potential effects of policy changes, both large and small," says Garry O'Grady, Senior Vice President of the Pharmaceutical Institute. "It is important for pharmaceutical and biotech companies to keep their teams abreast of these potential policy changes and to understand the possible implications to their business."
The Introduction to Health Policy e-course, developed in partnership with subject-matter experts from Campbell Alliance, provides team members with the background necessary to understand the potential policy changes facing the industry, as well as the impacts of these changes on the way companies develop, market, and sell their products. The 2-hour e-course consists of four comprehensive modules, providing team members with a solid foundation on current health policy issues, including
- Health Policy Stakeholders -- This module provides an introduction to key players in the development of health policy, their roles, and the differing perspectives they "bring to the table." Team members will also become familiar with leaders spearheading current efforts to achieve health insurance reform.
- US Health Coverage - A Current View -- As a necessary backdrop for understanding healthcare reform efforts, this module provides an overview of the existing health insurance landscape in the US. The roles played by both commercial health plans and the major government insurance programs are explored.
- Health Reform Options -- For the first time in decades, major health insurance reform is at the top of the Capitol Hill agenda. This module clarifies the confusing array of reform options that are currently under consideration and explains the perspectives of advocates and opponents. Possible implications of change for the pharmaceutical and biotechnology sector are explored.
- Hot Topics -- Health reform isn't the only front-burner health policy issue on Capitol Hill today. This module explores recent or proposed "movement" on five other pressing issues related to healthcare quality and cost, including Medicare Part D non-interference clause, comparative effectiveness research, drug reimportation, health information technology, and follow-on biologics. The discussion spotlights concerns that these issues have aroused in the pharmaceutical and biotechnology industry.
For more information on the Introduction to Health Policy e-course, please visit
For more information on the Managed Markets Excellence(TM) e-course series, please visit
About the Pharmaceutical Institute
Pharmaceutical Institute is a leading provider of specialized training programs for the pharmaceutical and biotech industry. We partner with subject matter experts from our parent company, Campbell Alliance, to develop highly-impactful distance learning solutions for professionals within all major pharmaceutical company functions including Brand Management, Business Development, Clinical Development, Managed Markets, Medical Affairs, Sales, and Trade and Distribution. The Pharmaceutical Institute is based in Raleigh, N.C. For more information, please visit www.pharmainstitute.com.
Related biology technology :1
|SOURCE Pharmaceutical Institute|
Copyright©2009 PR Newswire.
All rights reserved
. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes2
. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results3
. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results4
. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML5
. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 20076
. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 20077
. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results8
. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences9
. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer10
. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products11
. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences